NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments.
Zentalis Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma and the ongoing enrollment in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC). The company's cash, cash equivalents, and marketable securities totaled $366.8 million as of September 30, 2021.
- Initiated a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma.
- Enrollment is ongoing in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC).
- Published seminal research on the discovery of ZN-c3 in the Journal of Medicinal Chemistry.
- The Company’s virtual R&D day will be hosted on Thursday, December 16, 2021 at 11:00 a.m. EST
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$400K
Forward guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of September 30, 2021 will be sufficient to fund operating expenses and capital expenditures requirements into the third quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2021
-1.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+0.8%
Avg return
30 days after
60%
15 / 25 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.1% | -3.2% | — | |
| Q1 2026 | +3.9% | -1.7% | -15.0% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q2 2025 | +5.1% | +2.2% | +26.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro